This conference — held in partnership with the Champalimaud Foundation and hosted at the Champalimaud Centre for the Unknown, its state-of-the-art treatment and research facility in Lisbon, Portugal — will cover the latest basic and clinical research developments in ocular oncogenesis and oncology, and consider them in the context of the systemic cancer field.
The scientific program will focus on malignant tumors of the eye, including: choroidal malignant melanoma, retinoblastoma and primary vitreoretinal lymphoma, and will cover:
- epidemiological studies in ocular tumors
- research into basic pathogenic mechanisms of oncogenesis, including genetics, cell biology and immunology
- development and evaluation of ocular tumor diagnostics (and classification)
- results of new human clinical trials for ocular tumor therapies
- application of advances in systemic oncogenesis and oncology to the ocular field
The conference will include podium sessions, with opening and closing keynote lectures, a tour of the Champalimaud Centre for the Unknown, poster sessions and multiple opportunities for attendees to network. Speakers will be international experts in oncogenesis and oncology, from the Champalimaud Centre for the Unknown and other ophthalmic centers around the globe.
At the conclusion of the conference, participants will:
- Be aware of the areas of current research activity in ocular oncogenesis and oncology.
- Have an up-to-date understanding of ocular tumor pathogenesis.
- Be knowledgeable in the results of clinical research relating to ocular tumor diagnostics, treatments and outcomes.
|Joan O’Brien, MD
Scheie Eye Institute
University of Pennsylvania
|Jacob Pe'er, MD, FARVO
Hadassah-Hebrew University Medical Center
|Justine Smith, MBBS, PhD
|David Wilson, MD
Casey Eye Institute
Oregon Health & Science University
Champalimaud Foundation Scientific Program Liaison
|Antonio Parreira, MD, PhD|
Guests of Honor
|Jose´ Cunha-Vaz, MD, PhD|
|Martine Jager, MD, PhD, FARVO|
Leiden University Medical Center